Codexis appoints David Butler to strategic advisory board
Reuters2026/08/03 13:01- Codexis named David Butler to its Strategic Advisory Board to advise on enzymatic manufacturing for siRNA and other oligonucleotide therapeutics.
- Butler most recently served as CTO at Hongene Biotech from 2023 to 2026.
- He previously led chemistry groups at Wave Life Sciences, Korro Bio, Alltrna.
- Carole Cobb stepped down from the Strategic Advisory Board.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
US military strikes Iranian oil tanker, triggering geopolitical risks as Brent crude nears $97 mark
Following the US military's attack on Iranian oil tankers and Iran's announcement of new restricted navigation zones outside the Strait of Hormuz, market concerns over prolonged disruptions in key energy transport routes have intensified, leading to a sharp rise in international oil prices.
Geopolitical tensions overshadowing production cuts: OPEC+ maintains quotas unchanged, paper adjustments fail to resolve physical supply dilemmas
OPEC+ major oil producers, led by Saudi Arabia and Russia, held a monthly video conference last Sunday and decided to keep the crude oil production quota for October unchanged, continuing the previous tone of stable production following a series of symbolic production increases.
IX Biopharma seeks SGX-ST trading halt lift for shares in Singapore
No Public Money Behind El Salvador’s New Bitcoin, IMF Confirms
Crypto prices
More
